Abstract
Abstract Aims To find genetic markers associated with response to statins in a general population. Methods Data from baseline (2003–2006), first (2009–2012) and second (2014–2017) follow-ups of a population-based, prospective cohort study in Lausanne, Switzerland. Management of dyslipidemia was assessed according to the Swiss GSLA or European ESC/EAS guidelines based on LDL-cholesterol levels. The associations between 51 SNPs and dyslipidemia control using statins was performed. Results 617, 844 and 798 participants of the baseline, first and second follow-ups (UPs) were included. Prevalence of adequately managed dyslipidemia was 70%, 68.5% and 83.6% at baseline, first and second FUs, respectively. Out of the 51 SNPs, most statistically significant (p<0.05) associations with dyslipidemia control were found for SNPs related with SLCO1B1 (Solute Carrier Organic Anion Transporter Family Member 1B1) and ABCB1 (ATP Binding Cassette Subfamily B Member1), see Table. Still, most associations failed to replicate within survey periods or guidelines. Conclusion SLCO1B1 and ABCB1 polymorphisms might interact with response to statins. The use of genetic markers to guide statin prescription is not recommended, but for the future studies the impact of SLCO1B1 and ABCB1 in statin therapy should be further explored investigated. Funding Acknowledgement Type of funding sources: None. Table 1. SNPs and dyslipidemia: their association
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
